临床荟萃

• 论著 • 上一篇    下一篇

外周血单倍体造血干细胞移植后巨细胞病毒感染临床研究

  

  1. 郑州大学第一附属医院 血液科,河南 郑州 450052
  • 出版日期:2016-09-05 发布日期:2016-08-31
  • 通讯作者: 通信作者:万鼎铭,Email: wwddmm@vip.sina.com
  • 基金资助:
    河南省科技厅科技攻关项目(162102310130)

Clinical study of cytomegalovirus infection and preemptive therapy after  haploidentical peripheral blood hematopoietic stem cell transplantation

  1. Department of Hematology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
  • Online:2016-09-05 Published:2016-08-31
  • Contact: Corresponding author: Wan Dingming, Email: wwddmm@vip.sina.com

摘要: 目的探讨外周血单倍体造血干细胞移植(haploidentical peripheral blood hematopoietic stem cell transplantation,HIDPBSCT )后巨细胞病毒(CMV)感染的临床特点及抢先治疗的临床意义。方法对本院血液科2010年3月至2015年3月69例外周血单倍体造血干细胞移植患者巨细胞病毒感染情况进行回顾性分析,统计移植后CMV感染的累积发生率、发生中位时间、抢先治疗有效率、转阴中位时间以及对移植患者长期生存(5年)的影响。结果移植后51例(73.9%)发生CMV血症,发生中位时间为移植后36天(14~120天);80.4%(41/51)的患者经抗病毒抢先治疗后转为阴性,转阴中位时间为21天(7~82天),其中2例患者发生巨细胞病毒肺炎,未发生CMV血症组5年生存率为50%,CMV血症组5年生存率为52.9%,两组差异无统计学意义(P=0.829)。结论HIDPBSCT有较高的CMV血症发生率,抢先治疗能有效阻止CMV血症患者发病。

关键词: 造血干细胞移植, 巨细胞病毒感染, 危险因素, 移植物抗宿主病

Abstract: ObjectiveTo analyze the clinical characteristics  of cytomegalovirus(CMV) infection after  human leukocyte antigen(HLA) haploidentical peripheral blood hematopoietic stem cell transplantation(HDIPBSCT) and the effect of the preemptive treatment. MethodsThe study enrolled 69 patients who underwent HDIPBSCT in the Department of Hematology of our hospital from Mar 2010 to Mar 2015. The CMV infection rate, the median time when CMVDNA was positive at the first time, the response rate of the preemptive treatment and the median time of CMVDNA turning negative were analyzed. Fiveyear survival rate was compared between the patients with or without CMV infection. ResultsThe results indicated that CMV viremia was 73.9%(51/69).The median time of CMV when CMVDNA was positive at the first time was 36 d(14120 d)after HIDPBSCT.After the preemptive treatment, 80.4%(41/51) of the patients with CMV viremia turned negative. The median time of CMVDNA turning negative were 21 d(782 d), only two patients died of CMV pneumonia. Fiveyear survival rate of the patients with or wihout CMV viremia was  respectively  52.9% and 50% (P>0.05). ConclusionThe incidence of CMV infection is high after HIDPBSCT. The preemptive treatment can effectively prevent the progression of CMV viremia to CMV disease.

Key words: hematopoietic stem cell transplantation; cytomegalovirus infections, risk factors, graft vs host disease